Badanie obserwacyjne oceniające skuteczność i bezpieczeństwo stosowania cemiplimabu u pacjentów z zaawansowanym niedrobnokomórkowym rakiem płuca (NSCLC) w rutynowej praktyce klinicznej w Europie (CEMI-LUNG) (CEMI-LUNG)
An Observational Study to Assess the Effectiveness and Safety of Cemiplimab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG)
This study is focused on patients with non-small cell lung cancer (NSCLC) and have been prescribed a cemiplimab (Libtayo®) based treatment regimen under standard care.
The goal of this study is to learn more about the use, benefits, and safety of cemiplimab based treatment regimens in participants with NSCLC.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Originally registered as OBS17104 by Sanofi; transitioned to REGN 05Jul2023.
The recruitment period will be 48 months. Data will be collected during routine clinical visits approximately every three months while the patient is on cemiplimab treatment and then approximately every six months for up to 24 months after cemiplimab discontinuation. Patients will be followed from cemiplimab treatment initiation until death, loss to follow-up, study withdrawal, or to the end of the study period (72 months after study launch), whichever occurs first.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Salzburg, Austria, 5020
- Salzburger Landeskliniken (SALK)
-
-
Carinthia
-
Klagenfurt, Carinthia, Austria, 9020
- Klinikum Klagenfurt
-
-
-
-
-
Angers, Francja, 49000
- Centre Hospitalier Universitaire Angers
-
Clermont-Ferrand, Francja, 63003
- Center Hospitalier Universitaire (CHU) of Clermont
-
Le Mans, Francja, 72037
- Centre Hospitalier - Le mans
-
Paris, Francja, 75020
- Hopital Tenon
-
-
Alsace
-
Mulhouse, Alsace, Francja, 68100
- Le Groupe Hospitalier de la Region de Mulhouse et Sud Alsace, Emile Muller Hospital
-
-
Bas-Rhin
-
Strasbourg, Bas-Rhin, Francja, 67000
- Hopitaux Universitaires de Strasbourg
-
-
Bouches-du-Rhône
-
Marseille, Bouches-du-Rhône, Francja, 13915
- APHM - Hopital Nord
-
-
Vaucluse
-
Avignon, Vaucluse, Francja, 84918
- Sainte Catherine Institut du Cancer Avignon Provence
-
-
Vienne
-
Poitiers, Vienne, Francja, 86021
- Centre Hospitalier Universitaire (CHU) de Poitiers
-
-
-
-
-
Almería, Hiszpania, 04009
- Hospital Torrecardenas
-
Jaén, Hiszpania, 23007
- University Hospital of Jaen
-
Lleida, Hiszpania, 25198
- Hospital Arnau de Vilanova
-
Santa Cruz de Tenerife, Hiszpania, 38010
- Hospital Universitario Nuestra Senora de Candelaria
-
Tarragona, Hiszpania, 43204
- Hospital Universitari Sant Joan de Reus
-
-
Andalusia
-
Málaga, Andalusia, Hiszpania, 29010
- Hospital Universitario Virgen De La Victoria Malaga
-
-
Barcelona
-
Sabadell, Barcelona, Hiszpania, 08208
- Parc Tauli Sabadell Hospital Universitari
-
-
Cadiz
-
Jerez de la Frontera, Cadiz, Hiszpania, 11407
- Hospital Universitario De Jerez
-
-
Castellon
-
Castellon, Castellon, Hiszpania, 12002
- Consorcio Hospitalario Provincial de Castellon
-
-
Galicia
-
Ferrol, Galicia, Hiszpania, 15405
- Complejo Hospitalario Universitario de Ferrol - Hospital Naval
-
Vigo, Galicia, Hiszpania, 36204
- Hospital Universitario Alvaro Cunqueiro
-
-
-
-
-
Berlin, Niemcy, 14089
- Gemeinschaftskrankenhaus Havelhoehe
-
Dortmund, Niemcy, 44263
- Gesellschaft fur Onkologische Studien Dortmund mbH (Gefos)
-
Halle, Niemcy, 06120
- Krankenhaus Martha-Maria Halle-Doelau gGmbH
-
-
Baden-Wurttemberg
-
Konstanz, Baden-Wurttemberg, Niemcy, 78464
- Klinikum Konstanz
-
-
Bavaria
-
München, Bavaria, Niemcy, 81925
- Staedtisches Klinikum Muenchen Bogenhausen
-
Nuremberg, Bavaria, Niemcy, 90419
- Nuremberg Hospital, Campus North
-
-
Georgsmarienhuette
-
Georgsmarienhütte, Georgsmarienhuette, Niemcy, 49124
- Franziskus Hospital Harderberg
-
-
Lower Saxony
-
Rotenburg (Wümme), Lower Saxony, Niemcy, 27356
- Agaplesion Diakonieklinikum Rotenburg
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Niemcy, 48145
- St. Franziskus Hospital Münster
-
Troisdorf, North Rhine-Westphalia, Niemcy, 53840
- Haematologisch Onkologische Schwerpunktpraxis - Troisdorf
-
-
Saxony
-
Leipzig, Saxony, Niemcy, 4347
- Pneumologische Praxis PD Dr. Med Christian Gessner
-
-
-
-
-
Catania, Włochy, 95123
- AO Universitaria Policlinico Vittorio Emanuele
-
Milan, Włochy, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Modena, Włochy, 41124
- Azienda Ospedaliero-Universitaria di Modena
-
Naples, Włochy, 80131
- Istituto Nazionale Tumori IRCCS Fondazione G Pascale
-
Naples, Włochy, 80131
- AORN dei Colli
-
Pavia, Włochy, 27100
- Fondazione IRCCS Policlinico San Matteo
-
Taranto, Włochy, 74010
- Azienda Sanitaria Locale (ASL) Taranto
-
-
Catania
-
Misterbianco, Catania, Włochy, 95065
- Humanitas Istituto Clinico Catanese
-
-
Firenze
-
Florence, Firenze, Włochy, 50134
- AOU Careggi
-
-
Friuli Venezia Giulia
-
Udine, Friuli Venezia Giulia, Włochy, 33100
- Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) Santa Maria della Misericordia
-
-
Milan
-
Rozzano, Milan, Włochy, 20089
- IRCCS Humanitas Research Hospital
-
-
Piedmont
-
Orbassano, Piedmont, Włochy, 10043
- San Luigi Gonzaga University Hospital
-
-
Tuscany
-
Pisa, Tuscany, Włochy, 56126
- Ospedale Di Cisanello Azienda Ospedaliero Universitaria
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
The source population for this study will be patients with either locally advanced NSCLC not suitable for definitive chemoradiation or metastatic NSCLC and who are initiating a cemiplimab-based regimen of treatment as part of routine clinical practice at the time of study enrollment. The study will aim to enroll approximately 500 adult patients from up to 50 sites across Europe.
Opis
Key Inclusion Criteria:
- At least 18 years of age at the time of cemiplimab treatment initiation
- Has been diagnosed with histologically or cytologically documented squamous or non-squamous NSCLC
- Prescribed a cemiplimab-based regimen as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the Summary of Product Characteristics (SmPC).
- Can understand and complete the study-related questionnaires
- Must be legally capable of providing written consent for participation in the study and have signed informed consent prior to any study activities
Key Exclusion Criteria:
- Has received cemiplimab prior to enrollment
- Has uncontrolled autoimmune disease
- Has a contraindication to cemiplimab as noted in the local SmPC
- Is concurrently participating in any other study of an investigational drug or procedure
- Has cognitive impairment or other medical condition that, in the opinion of the investigator, would interfere with the ability to complete the study-related questionnaires
NOTE: Other protocol-defined inclusion/exclusion criteria apply
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Cohort 1
Cemiplimab monotherapy |
solution for injection via intravenous (IV) infusion
Inne nazwy:
|
|
Cohort 2
Cemiplimab in combination with platinum-based chemotherapy |
solution for injection via intravenous (IV) infusion
Inne nazwy:
IV administration |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall survival (OS)
Ramy czasowe: Up to 72 months
|
Date and primary cause of death |
Up to 72 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall Response Rate (ORR)
Ramy czasowe: Up to 72 months
|
Defined as the proportion of patients with a complete response or partial as the physician-reported best overall response. |
Up to 72 months
|
|
Duration of Response (DoR)
Ramy czasowe: Up to 72 months
|
Defined among responders (patients with a complete response or partial response) as the time from the date of the first response after cemiplimab treatment initiation until the first date of disease progression or death due to any cause. |
Up to 72 months
|
|
Time to Response (TTR)
Ramy czasowe: Up to 72 months
|
Defined as the time from the first cemiplimab dose until the date of first response observed for that patient. Patients who die during the study will be censored using the date of the last valid disease assessment). |
Up to 72 months
|
|
Progression-Free Survival (PFS)
Ramy czasowe: Up to 72 months
|
Defined as the time from the first dose of cemiplimab until the date of the first documented tumour progression or death due to any cause. |
Up to 72 months
|
|
Time to first subsequent anti-NSCLC treatment (TTST)
Ramy czasowe: Up to 72 months
|
Defined as the time from the first cemiplimab dose until the date of the first subsequent anti-NSCLC treatment. |
Up to 72 months
|
|
Incidence of treatment-related adverse events (TR-AEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Ramy czasowe: Up to 72 months
|
Number of patients with treatment related adverse events occurring during treatment |
Up to 72 months
|
|
Incidence of treatment-related serious adverse events (TR-SAEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Ramy czasowe: Up to 72 months
|
Number of patients with serious treatment related adverse events occurring during treatment |
Up to 72 months
|
|
Incidence and severity of immune-mediated adverse events (imAEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Ramy czasowe: Up to 72 months
|
Number of patients with immune-mediated adverse events and serious immune-mediated adverse events occurring during treatment |
Up to 72 months
|
|
Incidence and severity of infusion related reactions (IRRs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Ramy czasowe: Up to 72 months
|
Number of patients with infusion related reactions and serious infusion related reactions adverse events occurring during treatment |
Up to 72 months
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Clinical Trial Management, Regeneron Pharmaceuticals
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- R2810-ONC-2325
- U1111-1275-9867 (Identyfikator rejestru: ICTRP)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .